Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $8.25
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on RenovoRx and raises the price target from $8 to $8.25.
September 12, 2024 | 10:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital's analyst Edward Woo has reaffirmed a Buy rating on RenovoRx and increased the price target from $8 to $8.25, indicating a positive outlook.
The reaffirmation of a Buy rating and a slight increase in the price target by a reputable analyst suggests confidence in RenovoRx's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100